AHPA Alerts

Webinar presenters will explain ways to ensure your marketing claims for herbal immune support products are substantiated, truthful and not misleading. Industry experts will review several methods they’ve used to ensure their dietary supplement product claims are well substantiated, including: randomized, controlled clinical trials on a well-known elderberry product; in vitro testing to support the legitimacy of the product; and the relevance of use and training in substantiating the effectiveness of traditional Chinese herbal formulations.

This free webinar will provide practical information on how best to resume post-quarantine business operations while protecting your workforce. Learn what personal protective equipment and workspace adaptations should be implemented and how to manage ongoing business risks and liabilities. Additionally, hear from experts about how to be proactive and search for, and then correct, workplace conditions that could increase risk of COVID-19 infections.

This webinar provides guidance and practical tips on how to successfully market your hemp-derived products consistent with the requirements of the FDA and FTC. An FTC representative provides FTC’s perspective, summarizes recent enforcement actions, and discusses the level of substantiation respondents in those actions possessed or did not possess. Industry attorneys address legal standards, today’s ever-evolving regulatory environment, and the lawsuit risks and liabilities marketers of hemp products face.

To help the herbal products industry understand the evolving regulatory landscape for hemp and hemp-derived cannabidiol (CBD) products, AHPA has updated its free Hemp-CBD Status Report to include recent actions taken by the Food and Drug Administration (FDA) and the U.S. Department of Agriculture (USDA).

The new validation and approval will allow laboratories to evaluate hemp for tetrahydrocannabinol (THC) on a dry-weight basis, as described by the U.S. Department of Agriculture’s Interim Final Rule governing the production of hemp under the 2018 Agriculture Improvement Act, known as the Farm Bill.

This webinar provides an overview of dietary supplement current good manufacturing (cGMP) requirements for hemp-CBD products. Legal and industry experts provide strategies and resources to comply and document compliance with  federal manufacturing requirements designed to ensure supplement product quality and safety.

This webinar is designed to help businesses in the dietary supplement industry understand the elements of current Good Manufacturing Practice (cGMP) regulations (21 CFR 111) that have been the primary focus of FDA inspections. This knowledge will assist businesses in better allocating and directing their compliance resources.

AHPA is presenting a two-day Sports Nutrition Congress Aug. 25-26 in Portland, OR and in conjunction with AHPA's Hemp-CBD Supplement Congress. AHPA's Sports Nutrition Congress is the first of its kind event that will showcase industry experts discussing key sports nutrition industry issues to provide the most up-to-date information, resources and practical tools and guidelines to help ensure the long-term success of your business. You will not want to miss this unique event,

register now!

The Oregon Department of Justice (OR DOJ) has temporarily adopted a rule declaring it “unfair and deceptive” (and thus unlawful) to represent that any product “will prevent, treat, diagnose, mitigate, or cure coronavirus, COVID-19 or a related condition, without first having competent and reliable scientific evidence upon which to base a reasonable belief in the truth of the representation.” The temporary rule is effective for six months, until October 14, 2020.

AHPA and the Council for Responsible Nutrition (CRN) filed joint comments last week to reiterate significant concerns to the Oregon Department of Justice (OR DOJ) about a Proposed Rule that would create a private right of action for opportunistic plaintiffs' lawyers motivated by the potential for recovery rather than the public interest.